{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+Neoplasms", "query": { "condition": "Esophageal Neoplasms" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1095, "total_pages": 110, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+Neoplasms&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T17:52:13.124Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04068896", "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Metastatic Castration-resistant Prostate Cancer", "Bladder Cancer", "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Ovarian Cancer", "Head Neck Squamous Cell Carcinoma", "Prostate Cancer" ], "interventions": [ { "name": "NGM120 30mg", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg", "type": "BIOLOGICAL" }, { "name": "NGM120 30mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg Q3W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-10-16", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068896" }, { "nct_id": "NCT00591123", "title": "Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Adenocarcinoma of the Esophagus", "Metastatic Adenocarcinoma of the Esophagus", "Unresectable Adenocarcinoma of Gastric Cardia", "Metastatic Adenocarcinoma of Gastric Cardia" ], "interventions": [ { "name": "FOLFOX", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2007-12", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591123" }, { "nct_id": "NCT04426669", "title": "A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Epithelial Cancer", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Cancer, Gastrointestinal", "Gastrointestinal Cancer", "Colo-rectal Cancer", "Pancreatic Cancer", "Gall Bladder Cancer", "Colon Cancer", "Esophageal Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tumor-Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intima Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 23, "start_date": "2020-05-15", "completion_date": "2026-01-22", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04426669" }, { "nct_id": "NCT03539822", "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophageal Adenocarcinoma", "Hepatocellular Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-10-22", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 2, "location_summary": "Westwood, Kansas • Pittsburgh, Pennsylvania", "locations": [ { "city": "Westwood", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03539822" }, { "nct_id": "NCT01102088", "title": "Simultaneous Integrated Boost (SIB) in Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2010-04", "completion_date": "2019-06-08", "has_results": false, "last_update_posted_date": "2020-05-22", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01102088" }, { "nct_id": "NCT02013154", "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Neoplasms", "Adenocarcinoma of the Gastroesophageal Junction", "Gastroesophageal Cancer", "Squamous Cell Carcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "DKN-01 150 mg", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "DKN-01 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2014-05-05", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013154" }, { "nct_id": "NCT01747551", "title": "FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ziv-aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2013-01", "completion_date": "2017-07-26", "has_results": true, "last_update_posted_date": "2020-02-10", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747551" }, { "nct_id": "NCT00256269", "title": "Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastroesophageal Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2005-06", "completion_date": "2007-02-07", "has_results": false, "last_update_posted_date": "2018-01-26", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00256269" }, { "nct_id": "NCT05795595", "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Cervical Carcinoma", "Esophageal Carcinoma", "Pancreatic Adenocarcinoma", "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "CTX131", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CRISPR Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2023-03-13", "completion_date": "2025-09-18", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 7, "location_summary": "Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05795595" }, { "nct_id": "NCT03819088", "title": "Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastric Carcinoma", "Liver and Intrahepatic Bile Duct Carcinoma", "Unresectable Esophageal Carcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Zinc", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 17, "start_date": "2019-04-17", "completion_date": "2022-03-22", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-06-07T17:52:13.124Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819088" } ] }